AKT1 and cancer: BMS-536924, an ATP-competitive IGF1R inhibitor, can suppress the IGF1R-induced phosphorylation of phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT), consequently repressing cancer cell proliferation and differentiation [31–34].